Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557471 | 0.83 | MAOA (0.42) | DGAT1MAOAMAOBCYP2D6CA2 | |
| SCHEMBL241533 | 0.82 | DGAT1 (0.46) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL27275384 | 0.80 | MAOA (0.41) | DGAT1MAOAMAOBCYP2D6CA2 | |
| Methyl Alcohol SCHEMBL27995686 | 0.79 | DGAT1 (0.44) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL2086711 | 0.79 | DGAT1 (0.37) | DGAT1MAOAMAOBCYP2D6CA2 | |
| SCHEMBL2975348 | 0.78 | DGAT1 (0.39) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL3371966 | 0.77 | DGAT1 (0.40) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL8428953 | 0.77 | DGAT1 (0.35) | DGAT1MAOAMAOBCYP2D6CA2 | |
| SCHEMBL27400387 | 0.77 | CA12 (0.37) | DGAT1CYP2D6CA2CA12CA14 | |
| SCHEMBL2648388 | 0.77 | DGAT1 (0.42) | DGAT1CYP2D6CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210776-A1 | CATIONIC STEROIDAL ANTIMICROBIALS | BRIGHAM YOUNG UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-9387215-B2 | Animal feed including cationic cholesterol additive and related methods | BRIGHAM YOUNG UNIVERSITY (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160193232-A1 | TREATMENT AND PREVENTION OF MASTITIS | BRIGHAM YOUNG UNIVERSITY (US) | 2016-07-07 | — | — | US | disclosed |
| US-9314472-B2 | Treatment and prevention of mastitis | BRIGHAM YOUNG UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150374719-A1 | METHODS FOR TREATING FUNGAL INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140336131-A1 | METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN | BRIGHAM YOUNG UNIVERSITY (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140315873-A1 | ANIMAL FEED INCLUDING CATIONIC CHOLESTEROL ADDITIVE AND RELATED METHODS | BRIGHAM YOUNG UNIVERSITY (US) | 2014-10-23 | — | — | US | disclosed |
| US-8815901-B2 | Quinoline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8674099-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2014-03-18 | — | — | US | disclosed |
| US-8536175-B2 | Quinoxaline carboxamide derivatives as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| WO-2004056823-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210776-A1 | CATIONIC STEROIDAL ANTIMICROBIALS | CCL11, CCL5, SERPINA6 | DGAT1 2155/4885MAOA 3766/4885MAOB 3756/4885 |
| US-20140315873-A1 | ANIMAL FEED INCLUDING CATIONIC CHOLESTEROL ADDITIVE AND RELATED METHODS | PIGS, CETP, CYP46A1 | DGAT1 498/4885MAOA 2016/4885MAOB 2966/4885 |
| US-20120309766-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | DGAT1 4037/4885MAOA 454/4885MAOB 418/4885 |
| US-20140336131-A1 | METHODS FOR TREATING INFLAMMATION, AUTOIMMUNE DISORDERS AND PAIN | MPO, SSB, MMP8 | DGAT1 1764/4885MAOA 4018/4885MAOB 3948/4885 |
| US-20120309741-A1 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, BTK, PDXK | DGAT1 4037/4885MAOA 454/4885MAOB 418/4885 |
| US-20160193232-A1 | TREATMENT AND PREVENTION OF MASTITIS | NFATC1, CYP11A1, CTSA | DGAT1 3487/4885MAOA 2158/4885MAOB 4081/4885 |
| US-20150374719-A1 | METHODS FOR TREATING FUNGAL INFECTIONS | ERG28, ASAH2, DPM1 | DGAT1 2077/4885MAOA 2768/4885MAOB 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.